A two year observation of the process of applying recombinant IGF-1 to treat short stature in children with primary IGF-1 deficiency - case reports of 3 patients

A two year observation of the process of applying recombinant IGF-1 to treat short stature in children with primary IGF-1 deficiency - case reports of 3 patients

Growth deficiency is one of the most frequent causes of referral to Endocrinology Outpatient Clinic. IGF-1 (insulin-like growth factor 1) deficiency is one of the rarest causes of short stature. In 2009 in Poland a therapeutic programme was set up for children with severe primary IGF-1 deficiency. T...

Full description

Saved in:
Bibliographic Details
Main Authors: Elżbieta Petriczko, Beata Wikiera, Anita Horodnicka-Józwa, Katarzyna Marcinkiewicz, Justyna Szmit-Domagalska, Andrzej Kędzia, Julia Durzyńska, Justyna Broniarczyk, Bartosz Gabryelczyk
Format: Article
Language:English
Published: Termedia Publishing House 2011-12-01
Series:Pediatric Endocrinology, Diabetes and Metabolism
Subjects:
insulin-like growth factor 1 (IGF-1)
short stature
</keyword> <keyword>
Online Access:http://cornetis.pl/pliki/ED/2011/4/ED_2011_4_233.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Growth deficiency is one of the most frequent causes of referral to Endocrinology Outpatient Clinic. IGF-1 (insulin-like growth factor 1) deficiency is one of the rarest causes of short stature. In 2009 in Poland a therapeutic programme was set up for children with severe primary IGF-1 deficiency. The authors present the data of three first polish patients qualified for the rhIGF-1 (recombinant human insulin-like growth factor 1) - mecasermin. The authors conclude that the treatment with rhIGF-1 significantly improves growth velocity in patients with IGF-1 deficiency. During two years of mecasermin treatment no serious side effects were noted.Niedobór wzrostu jest jednym z najczęstszych powodów wizyt dzieci w Poradniach Endokrynologicznych. Niedobór IGF-1 (insulin-like growth factor 1) jest jedną z rzadkich przyczyn niskorosłości. W Polsce od 2009 r. wprowadzono terapeutyczny program zdrowotny leczenia dzieci z ciężkim pierwotnym niedoborem IGF-1. Autorzy prezentują opis trzech pierwszych polskich pacjentów zakwalifikowanych do leczenia rhIGF-1 (recombinant human insulin-like growth factor 1). Autorzy podsumowują, że zastosowanie rekombinowanego ludzkiego IGF-1 w leczeniu niskorosłości powodowanej pierwotnym niedoborem IGF-1 wpływa znacząco na poprawę tempa wzrastania. W czasie 2-letniej obserwacji nie odnotowano poważnych skutków ubocznych terapii.
ISSN:2081-237X

Similar Items